熱門資訊> 正文
Celcuity获得批准的乳腺癌治疗gedatolisib
2026-07-15 04:58
- The US FDA has approved Celcuity's (CELC) Revtorpyk (gedatolisib) in combination with fulvestrant, with or without palbociclib, for HR+/HER- breast cancer following one line of endocrine therapy.
- Approval was based on results from the VIKTORIA-1 trial that showed significant improvement in progression-free survival with gedatolisib. Treatment also led to improvement in overall survival, objective response rate, and duration of response.
- Gedatolisib is dosed via intravenous infusion weekly on days 1, 8, and 15 of every 28-day cycle.
More on Celcuity
- Celcuity Inc. (CELC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
- Celcuity Inc. (CELC) Discusses VIKTORIA-1 Trial Results for PIK3CA Mutant Advanced Breast Cancer and Gedatolisib Efficacy - Slideshow
- Celcuity: Selloff On Yesterday's Data Unwarranted; Buy Rating Upheld
- Celcuity raises $500M in upsized 0.25% convertible notes sale
- Celcuity announces $400M convertible notes offering
推薦文章
華盛早報 | 終結14季淨賣出！伯克希爾Q2增持谷歌至前五大持倉；千億私募景林Q2清倉英偉達等美股科技股；馬斯克擬用FEL技術顛覆光刻機
美參議院加密監管法案投票推迟至9月 《清晰法案》落地前景不容樂觀
8月財報預告 | 中概財報齊襲！騰訊、京東打頭陣；英偉達月末放榜！能否打破「財報魔咒」？
港股周報 | 黃金股狂飆！靈寶黃金周升24%；段永平「被動減持」泡泡瑪特；藥明康德升近20%創新高
一周財經日曆 | 重磅財報周！騰訊、Lumentum、中芯國際輪番登場！美國7月CPI攜零售數據來襲
8月8日外盤頭條：伊朗內部辯論霍爾木茲協議措辭 非農爆冷削弱加息預期 SpaceX將自建發電廠保障電力供應
Palantir股價將創下自2024年以來最佳單周表現，該股已不再是AI領域的失意者
7月非農就業數據走弱，支持美聯儲維持利率不變，但加息選項並未徹底排除
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
